

DIAGNOSING AND MANAGING HEPATITIS C

REFERENCES

1. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA, Margolis HS. The prevalence of hepatitis C virus in the United States, 1988 through 1994. *N Engl J Med.* 1999;341(8):556–562.
2. Armstrong GL, Simard EP, Wasley A, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus (HCV) infection in the United States, 1999–2002. Presented at the 2004 New York State Department of Health Third Annual Hepatitis C Conference in New York City.
3. Tradati F, Colombo M, Mannucci PM, et al. A prospective multicenter study of hepatocellular carcinoma in Italian hemophiliacs with chronic hepatitis C. *Blood.* 1998;91:1173–1177.
4. Shehab TM, Sonnad SS, Lok AS. Management of hepatitis C patients by primary care providers in the USA: results of a national survey. *Journal of Viral Hepatitis.* 2001;8(5):377–383.
5. Strader DB, Wright T, Thomas DL, Seeff LB. AASLD Practice Guideline: Diagnosis, management, and treatment of hepatitis C. *Hepatology.* 2004;39(4):1147–1171.
6. Fernandez-Rodriguez CM, et al. Factors influencing the rate of fibrosis progression in chronic hepatitis C. *Digestive Diseases & Sciences.* 2004;49(11–12):1971–1976.
7. Westin J, Lagging LM, Spak F, Aires N, Svensson E, Lindh M, Dhillon AP, Norkrans G, Wejstal R. Moderate alcohol intake increases fibrosis progression in untreated patients with hepatitis C virus infection. *Journal of Viral Hepatitis.* 2002;9(3):235–241.
8. Highleyman L. HIV and hepatitis coinfection. *Bulletin of Experimental Treatments for AIDS.* Winter 2002/2003. Available at: www.thebody.com/sfaf/winter03/coinfection.html#twin. Accessed March 14, 2005.
9. PDQ Cancer Information Summary: Screening and Testing. Hepatocellular (Liver) Cancer: Health Professional. Available at: www.cancer.gov. Accessed March 21, 2005.
10. New York State Department of Health. Clinical guidelines for the medical management of hepatitis C. Available at www.health.state.ny.us/diseases/communicable/hepatitis/docs/hepc_guidelines.pdf. Accessed October 21, 2005.
11. Imazeki F, Yokosuka O, Fukai K, Saisho H. Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study. *Hepatology.* 2003;38(2):493–502.
12. Roberts EA, Yeung L. Maternal-infant transmission of hepatitis C virus infection. *Hepatology.* 2002;36(5 Suppl 1):S106–113.
13. Management of hepatitis C: 2002. *NIH Consensus State Sci Statements.* 2002 Jun 10–12;19(2):1–46.
14. Sulkowski M, et al. Peginterferon alfa-2a does not alter the pharmacokinetics of methadone in patients with chronic hepatitis C undergoing methadone maintenance therapy. *Clin Pharmacol Ther.* 2005;77(3):214–224.
15. Cournot M, et al. Management of hepatitis C in active drug users: experience of an addiction care hepatology unit. *Gastroenterol Clin Biol.* 2004;28(6–7 Pt 1):533–539.
16. Van Thiel DH, Anantharaju A, Creech S. Response to treatment of hepatitis C in individuals with a recent history of intravenous drug use. *Am J Gastroenterol.* 2003;98(10):2281–2288.
17. Golub ET, et al. STRIVE Project. Screening for depressive symptoms among HCV-infected injection drug users: examination of the utility of the CES-D and the Beck Depression Inventory. *J Urban Health.* 2004;81(2):278–290.
18. Stuyt EB. Hepatitis C in patients with co-occurring mental disorders and substance use disorders: is tobacco use a possible risk factor? *Am J Addict.* 2004;13(1):46–52.
19. Johnson ME, Fisher DG, Fenaughty A, Theno SA. Hepatitis C virus and depression in drug users. *Am J Gastroenterol.* 1998;93:785–789.
20. Raison CL et al. Depressive symptoms during IFN-alpha/ribavirin therapy are associated with reduced viral clearance in patients with hepatitis C. Abstract 344 (poster). Program and Abstracts of the 54th AASLD. October 24–28, 2003. Boston, MA.